Alvotech (ALVO) Stock Price, Quote & News

Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indicatio...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: www.alvotech.com

Address:

9, Rue de Bitbourg, Luxembourg, Luxembourg

Toffik72 Aug. 4 at 3:41 PM

With the recent pullback, $ALVO is back inside the Bollinger Bands. The upper band is currently around $3.88. It looks like the move higher could become a bit more controlled again—but who knows, it's the market.

0 · Reply

SQUEAKSBANDIT Aug. 3 at 2:45 PM

$ALVO wow someone let the air out fast did i miss a pr/filing ?

0 · Reply

LSOTradingDesk Aug. 1 at 9:12 AM

$ALVO $IRWD 👀

0 · Reply

LSOTradingDesk Aug. 1 at 8:57 AM

$ALVO 👀

0 · Reply

JohnTill Jul. 31 at 3:08 PM

$ALVO Nice surprise today on the follow-through strength and sure appears to want to test the 200MA at 4.50 as the next stop. Eventually people will start front running the three drug approvals coming in Dec. and all the launches. I am just surprised it is this soon so maybe something else cooking?

4 · Reply

Toffik72 Jul. 30 at 12:00 PM

$ALVO DNB Carnegie (one of the leading Nordic investment banks) raises today its target price for Alvotech to SEK 60 (from SEK 50) and reiterates its Buy rating. New target price: SEK 60 ≈ USD 6.15 Previous target price: SEK 50 ≈ USD 5.12 https://www.placera.se/telegram/alvotech-dnb-carnegie-hojer-riktkursen-for-alvotech-till-60-kronor-50-upprepar-kop-20260730

1 · Reply

BioRich Jul. 29 at 8:17 PM

$MPLT Leads our Bios today with $ALVO, $CORT, and $OTLK following. If $CAPR gets a positve AdCom vote, it clearly takes the cake (800% upside for convincing "yes" vote?). Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

2 · Reply

RunnerSignals Jul. 29 at 8:06 PM

$ALVO $GKOS $OTLK $GDYN flipped the tape and closed with force. accumulation, short covering, or one last squeeze? the close holds the clue

0 · Reply

topstockalerts Jul. 29 at 8:06 PM

$ALVO this is the sort of action that sneaks onto your top list

0 · Reply

JohnTill Jul. 29 at 6:25 PM

$ALVO A little bull porn for you. Lets hope history repeats itself - at least in the short term. See bar in yellow. I am very doubtful this happens unless a surprise buyout war occurs but you never know.

1 · Reply

Alvotech announces successful closure of FDA inspection of manufacturing facility

Jul 3, 2026, 4:01 PM EDT - 4 weeks ago

Transactions of Managers and Closely Associated Persons

Jul 1, 2026, 4:00 AM EDT - 4 weeks ago

Alvotech further strengthens liquidity by securing term loan facility of $75 million

Jun 18, 2026, 4:00 AM EDT - 6 weeks ago

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

Jun 18, 2026, 4:00 AM EDT - 6 weeks ago

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

2026-06-16T11:08:35.000Z - 7 weeks ago

Alvotech $152M Spot Secondary priced at $3.75

Jun 15, 2026, 11:50 PM EDT - 7 weeks ago

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

2026-06-15T22:30:37.000Z - 7 weeks ago

Alvotech TBA Spot Secondary; price range $3.75-$undefined

2026-06-15T20:46:20.000Z - 7 weeks ago

Alvotech announces termination of ATM Prospectus Supplement with Jefferies

JEF

Jun 10, 2026, 10:30 AM EDT - 7 weeks ago

Alvotech Transcript: UBS Virtual Generics and Biosimilars Day

Jun 8, 2026, 8:40 AM EDT - 2 months ago

Alvotech Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-08T09:20:28.000Z - 2 months ago

Alvotech announces FDA acceptance of AVT16 BLA for review

TEVA

Jun 8, 2026, 4:00 AM EDT - 2 months ago

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

Jun 4, 2026, 9:20 AM EDT - 2 months ago

Alvotech Transcript: Jefferies Global Healthcare Conference 2026

2026-06-04T09:10:13.000Z - 2 months ago

Alvotech resubmits AVT05 BLAs to FDA

RDY TEVA

Jun 4, 2026, 4:00 AM EDT - 2 months ago

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

Jun 3, 2026, 4:30 PM EDT - 2 months ago

Main Results of 2026 Annual and Extraordinary General Meeting

Jun 2, 2026, 4:30 PM EDT - 2 months ago

Alvotech to present at upcoming investor conferences in June

Jun 1, 2026, 4:30 AM EDT - 2 months ago

Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland

May 13, 2026, 6:40 PM EDT - 2 months ago

Alvotech Transcript: Bank of America Global Healthcare Conference 2026

2026-05-11T09:25:06.000Z - 3 months ago

Alvotech announces cGMP surveillance inspection of Reykjavik facility

May 11, 2026, 4:30 AM EDT - 3 months ago

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

May 7, 2026, 8:00 AM EDT - 3 months ago

Alvotech Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Alvotech Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Alvotech Slides: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Alvotech Q1 2026 Financial Results

Apr 30, 2026, 4:30 PM EDT - 3 months ago

Alvotech Announces a Change in its Executive Team

Apr 24, 2026, 8:30 AM EDT - 3 months ago

Alvotech to Report Financial Results for the First Quarter of 2026

Mar 30, 2026, 7:58 PM EDT - 4 months ago

Alvotech files Annual Report with the SEC

Mar 30, 2026, 7:55 PM EDT - 4 months ago

Alvotech Publishes 2025 Annual Report

2026-03-24T12:50:32.000Z - 4 months ago

Alvotech price target lowered to $4 from $8 at Deutsche Bank

2026-03-24T09:37:15.000Z - 4 months ago

Alvotech price target lowered to $4 from $5 at Barclays

2026-03-23T23:30:12.000Z - 4 months ago

Alvotech price target lowered to $6 from $10 at UBS

2026-03-23T18:55:10.000Z - 4 months ago

Alvotech price target lowered to $4 from $5 at Barclays

Mar 19, 2026, 8:00 AM EDT - 4 months ago

Alvotech Earnings Call Transcript: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 4 months ago

Alvotech Annual report: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 4 months ago

Alvotech Earnings release: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 4 months ago

Alvotech Slides: Q4 2025

Mar 18, 2026, 6:15 PM EDT - 4 months ago

Alvotech Q4 2025 and Full Year 2025 Financial Results

Mar 4, 2026, 3:00 AM EST - 5 months ago

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Feb 11, 2026, 11:00 AM EST - 6 months ago

Alvotech Announces Increase in Number of Own Shares

Feb 5, 2026, 3:00 AM EST - 6 months ago

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

Feb 2, 2026, 3:00 AM EST - 6 months ago

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

Jan 8, 2026, 7:00 AM EST - 7 months ago

Alvotech Slides: SEB Nordic Seminar presentation

Jan 7, 2026, 5:00 PM EST - 7 months ago

Correction: Transactions of Managers and Closely Associated Persons

2026-01-06T12:21:28.000Z - 7 months ago

Alvotech CEO Robert Wessman to step down, Lisa Graver to succeed

Dec 31, 2025, 4:30 PM EST - 7 months ago

Alvotech Secures Term Loan Facility of USD 100 Million

Dec 29, 2025, 2:40 PM EST - 7 months ago

Changes in company's own shares

Dec 22, 2025, 3:26 PM EST - 8 months ago

Alvotech's Financial Calendar for 2026

Dec 22, 2025, 2:00 AM EST - 8 months ago

Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

2025-12-19T10:06:47.000Z - 8 months ago

Alvotech, Teva reach settlement and license agreement with Regeneron for AVT06

REGN TEVA

Dec 17, 2025, 2:30 AM EST - 8 months ago

Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering

Dec 16, 2025, 12:00 PM EST - 8 months ago

Alvotech Transcript: Investor Update

Dec 16, 2025, 12:00 PM EST - 8 months ago

Alvotech Press release: Investor Update

2025-12-08T21:25:13.000Z - 8 months ago

Alvotech initiated with an Underweight at Barclays

2025-12-03T11:53:22.000Z - 8 months ago

Alvotech price target lowered to $10 from $14 at Morgan Stanley

2025-11-24T10:35:12.000Z - 9 months ago

Alvotech announces European Commission approval for AVT03

Nov 24, 2025, 5:30 AM EST - 9 months ago

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

Nov 20, 2025, 4:00 AM EST - 9 months ago

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

Nov 18, 2025, 10:30 AM EST - 9 months ago

Alvotech Transcript: Jefferies London Healthcare Conference 2025

2025-11-18T14:36:54.000Z - 9 months ago

Alvotech price target lowered to $10 from $13 at UBS

Nov 13, 2025, 8:00 AM EST - 9 months ago

Alvotech Earnings Call Transcript: Q3 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

Alvotech Earnings release: Q3 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

Alvotech Slides: Q3 2025

Nov 12, 2025, 4:40 PM EST - 9 months ago

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Nov 10, 2025, 5:28 PM EST - 9 months ago

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Nov 6, 2025, 6:28 PM EST - 9 months ago

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Nov 6, 2025, 9:07 AM EST - 9 months ago

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

Nov 4, 2025, 4:01 PM EST - 9 months ago

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

2025-11-04T13:20:38.000Z - 9 months ago

Alvotech price target lowered to $10 from $28 at Northland

2025-11-04T10:00:10.000Z - 9 months ago

Deutsche downgrades Alvotech on AVT05 complete response letter

2025-11-04T01:05:28.000Z - 9 months ago

Alvotech downgraded to Hold from Buy at Deutsche Bank

2025-11-03T17:05:42.000Z - 9 months ago

Alvotech falls -34.2%

Nov 2, 2025, 5:12 PM EST - 9 months ago

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

Oct 22, 2025, 5:00 AM EDT - 10 months ago

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Oct 6, 2025, 4:40 AM EDT - 10 months ago

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

Sep 22, 2025, 6:15 AM EDT - 11 months ago

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

Sep 22, 2025, 4:30 AM EDT - 11 months ago

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

Sep 19, 2025, 7:45 AM EDT - 11 months ago

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

Sep 10, 2025, 10:45 AM EDT - 11 months ago

Alvotech Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 9:15 AM EDT - 11 months ago

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Toffik72 Aug. 4 at 3:41 PM

0 · Reply

SQUEAKSBANDIT Aug. 3 at 2:45 PM

$ALVO wow someone let the air out fast did i miss a pr/filing ?

0 · Reply

LSOTradingDesk Aug. 1 at 9:12 AM

$ALVO $IRWD 👀

0 · Reply

LSOTradingDesk Aug. 1 at 8:57 AM

$ALVO 👀

0 · Reply

JohnTill Jul. 31 at 3:08 PM

4 · Reply

Toffik72 Jul. 30 at 12:00 PM

1 · Reply

BioRich Jul. 29 at 8:17 PM

2 · Reply

RunnerSignals Jul. 29 at 8:06 PM

$ALVO $GKOS $OTLK $GDYN flipped the tape and closed with force. accumulation, short covering, or one last squeeze? the close holds the clue

0 · Reply

topstockalerts Jul. 29 at 8:06 PM

$ALVO this is the sort of action that sneaks onto your top list

0 · Reply

JohnTill Jul. 29 at 6:25 PM

1 · Reply

Head2top Jul. 29 at 5:11 PM

$ALVO Government Bankers knows too many common people are in this stock

1 · Reply

Head2top Jul. 29 at 4:52 PM

$ALVO Out inside of profit. This is crazy couldnt even hold above 3.45

0 · Reply

Toffik72 Jul. 29 at 3:16 PM

$ALVO MA50 and MA100 both on quite same 3.52-3.53 area, would be great to close above.

0 · Reply

jobix Jul. 29 at 3:03 PM

$ALVO Founder Robert wessman retired as ceo to continue with his other companies Could it be a deal to sell to teva or Fuji after fda approval is already in place? Finger crossed, looking really good from here...

1 · Reply

JohnTill Jul. 29 at 2:34 PM

$ALVO Sweet but unsurprising news from the FDA. On seeing the news added another chunk in the low 3s. Potentially we put in a bottom on this news. Now back to a 75% positon (3.19 avg). I had been waiting on adding in the last part under 3 and I might have missed the boat but that is what you get by trying to time the market over and over again. Next stop - gap fill.

0 · Reply

Head2top Jul. 29 at 2:23 PM

$ALVO Who is selling on the news today?

1 · Reply

diggs24 Jul. 29 at 2:21 PM

$ALVO hardly

0 · Reply

FlyingChemist01 Jul. 29 at 2:12 PM

$ALVO back to 4$? i hope the time line of my other investments supports the liqudity rotation i'd like to put in this. Goodluck to everyone! Timing is everything

0 · Reply

Toffik72 Jul. 29 at 2:05 PM

$ALVO Alvotech announces successful closure of FDA inspection of manufacturing facility https://www.placera.se/pressmeddelanden/alvotech-alvotech-announces-successful-closure-of-fda-inspection-of-manufacturing-facility-20260729

0 · Reply

Head2top Jul. 29 at 1:30 PM

$ALVO You must be rich

0 · Reply

Wisvest Jul. 29 at 12:02 AM

$ALVO it appears FDA has not accepted AVT05 and AVT06 resubmissions. It is almost two months now that BLAs were filed. I am wondering could be the issue if any because FDA inspection has been carried out in May 2026 before the submissions took place. Anyway, fingers crossed 🤞

2 · Reply

diggs24 Jul. 27 at 10:12 PM

$ALVO Waiting for under $3.

0 · Reply

Market Cap	1.24B
Revenue (ttm)	586.32M
Net Income (ttm)	27.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	74.11
Profit Margin	4.76%
Debt to Equity Ratio	-4.64

Volume	1,026,900
Avg Vol	916,008
Day's Range	N/A - N/A
Shares Out	301.81M
Stochastic %K	69%
Beta	0.19
Analysts	Sell
Price Target	$5.75